TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO)

TWD 8.03

(-0.5%)

Market Cap (In TWD)

643.37 Million

Revenue (In TWD)

22.74 Million

Net Income (In TWD)

-6.04 Million

Avg. Volume

226.14 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7.72-16.6
PE
-
EPS
-
Beta Value
-0.451
ISIN
TW0006549009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Hung-Chang Yuan
Employee Count
-
Website
https://www.taiwanj.com
Ipo Date
2015-10-21
Details
TaiwanJ Pharmaceuticals Co., Ltd., a specialty pharmaceutical company, develops and commercializes small molecules for chronic organ inflammation of metabolic, autoimmune, and infectious etiologies in Taiwan. The company also develops JKB-122 and JKB-121; and novel chemical entities for therapy to address chronic liver diseases and allergy/asthma. Its products target various diseases that include liver inflammation/liver fibrosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, autoimmune diseases, asthma, and atopic dermatitis. The company was incorporated in 2011 and is based in Zhubei, Taiwan.